These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 39360264)

  • 1. Discovery of
    Ji X; Chen X; Lin G; Ma K; Yang J; Zhao X; Chen S; Yang J
    Front Cell Neurosci; 2024; 18():1440409. PubMed ID: 39360264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
    Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
    Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
    Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
    Front Immunol; 2022; 13():974346. PubMed ID: 36275718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
    Xu J; Liu F; Li Y; Shen L
    Cell Mol Neurobiol; 2022 Apr; 42(3):709-722. PubMed ID: 32894375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
    Xu S; Wang Z; Ye J; Mei S; Zhang J
    Front Oncol; 2021; 11():729103. PubMed ID: 34568059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
    Zhang X; Sun X; Guo C; Li J; Liang G
    Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.
    Li G; Huang R; Fan W; Wang D; Wu F; Zeng F; Yu M; Zhai Y; Chang Y; Pan C; Jiang T; Yan W; Wang H; Zhang W
    Front Immunol; 2021; 12():800928. PubMed ID: 34956239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
    Shan E; Cao YN; Zhang Y; Chen W; Ren X; Zhu S; Xi X; Mu S; Ma M; Zhi T; Li X
    BMC Cancer; 2023 Sep; 23(1):846. PubMed ID: 37697240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
    Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
    Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
    [No Abstract]   [Full Text] [Related]  

  • 17. NCAPG as a Novel Prognostic Biomarker in Glioma.
    Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
    Front Oncol; 2022; 12():831438. PubMed ID: 35280743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
    Yang G; Tang S; Zhang J; Qin L
    World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggrephagy-related gene signature correlates with survival and tumor-associated macrophages in glioma: Insights from single-cell and bulk RNA sequencing.
    Zhang X; Tan J; Zhang X; Pandey K; Zhong Y; Wu G; He K
    Math Biosci Eng; 2024 Jan; 21(2):2407-2431. PubMed ID: 38454689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
    Wang H; Jiang C
    Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.